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6/j.bVoriconazole is increasingly used in allogeneic hematopoietic stem cell transplantation (HSCT) for prophy-
laxis and treatment of fungal infections. Hepatic dysfunction is common in patients undergoing HSCTandmay
have an impact on the clinical decision to institute voriconazole. We conducted a retrospective review of all
adult and pediatric HSCT recipients who received .2 consecutive doses of voriconazole between January
2005 and February 2008. Clinical hepatotoxicity was defined as the subjective attribution of liver enzyme
elevation (even a mild one) to hepatotoxicity because of voriconazole by the treating physician and leading
to discontinuation of voriconazole. Biochemical hepatotoxicity was defined as an elevation in one or more
liver enzymes to.3 times the upper limit of normal or .3 times the baseline value if abnormal at baseline.
Liver enzymes assessed included aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase,
and total bilirubin. Simple and multiple logistic regressions were used to define the risks for hepatic dysfunc-
tion. The Wilcoxon signed-rank test was used to assess the differences in liver function test values before,
during, and after the use of voriconazole. Sixty-eight of 200 patients (34%) developed hepatotoxicity while on
voriconazole. The median duration of voriconazole therapy was 72 days (range, 1-804 days). Biochemical
hepatotoxicity occurred in 51 patients (75%); clinical hepatotoxicity, in 17 patients (25%). Thirty-five
(51%) of the patients with hepatotoxicity required discontinuation of therapy. In simple logistic regression,
acute graft-versus-host disease (GVHD) was a risk factor for hepatotoxicity, and receipt of a T-cell depleted
allograft was protective. In multiple logistic regression, acute GVHD (P 5 .002) remained significant. There
were no cases of liver failure or death attributed to voriconazole. In this cohort of patients undergoing
allogeneic HSCT, the rate of hepatotoxicity while on voriconazole was 34%. In general, the hepatic dysfunc-
tion was mild and reversible. Voriconazole therapy with monitoring appears to be reasonably safe for use in
HSCT recipients at high risk for invasive fungal infections.
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functionINTRODUCTION
Voriconazole is a highly orally bioavailable azole
with broad activity against Candida and Aspergillus [1].
Triazole antifungal agents have been reported to cause
both cholestatic and hepatocellular injury [2,3]. Rarely,
fulminant hepatitis with hepatic necrosis is reported in
patients receiving triazoles. Severe hepatitis can beartment of Medicine, Services of Infectious Disease;
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bmt.2009.08.015enhanced on rechallenge and may be fatal [1,4-12]. In
clinical trials of voriconazole for the treatment of
invasive aspergillosis, a transaminase elevation was ob-
served in up to 19% of patients, with 4% representing
a serious hepatic adverse event. In an observational
study of patients with hematologic malignancies, up
to 69% developed a transaminase elevation; however,
only 7% of patients were considered to have clinically
significant hepatotoxicity (HT), which necessitated
discontinuation of voriconazole [13]. The incidence
of liver enzyme elevations and clinically significant
HT in recipients of hematopoietic stem cell transplan-
tation (HSCT) treated with voriconazole is not known.
Because of its broad antifungal spectrum, relatively low
toxicity rate, and convenience of administration, vori-
conazole is increasingly used for prophylaxis and treat-
ment of invasive fungal infections in HSCT recipients
who are already at risk for HT [3,14].
Liver dysfunction in allogeneic HSCT recipients
may result from various factors, including toxicity
Biol Blood Marrow Transplant 16:46-52, 2010 47Safety of Voriconazole in HSCTfrom the preparative regimen and other medications,
infection, veno-occlusive disease (VOD), and acute
and chronic graft-versus-host disease (aGVHD,
cGVHD) of the liver. These conditions may increase
the risk for HT associated with voriconazole use in
HSCT recipients. Over the last 3 years at our institu-
tion, voriconazole has been used for prophylaxis and
treatment of fungal infections in HSCT. We report
our experience on the hepatic safety of voriconazole
in this population.METHODS
We conducted a retrospective review to determine
the frequency of HT inHSCT recipients who received
voriconazole and to establish whether any additional
transplantation-related factors increased the risk for
HT. The study design was approved by the Memorial
Sloan-Kettering Cancer Center (MSKCC) Institu-
tional Review Board.
Study Patients
Adult and pediatric patients who underwent a first
allogeneic HSCT at MSKCC between January 2005
and July 2007 were included in the study. Patients
who received .2 consecutive doses of voriconazole
between January 1, 2005, and February 1, 2008, were
identified from pharmacy records. Those with liver en-
zyme values measured within 2 weeks before and dur-
ing voriconazole therapy were included in the study.
Definitions
Biochemical HT (BIO-HT) was defined as eleva-
tion of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (Alk
Phos), and/or total bilirubin (TBil) to.3 times the up-
per limit of normal or.3 times baseline if abnormal at
baseline, regardless of whether or not the abnormality
led to the discontinuation or interruption of voricona-
zole. Clinical HT (CL-HT) was based on the subjec-
tive assessment of the treating physician. CL-HT was
defined as mildly elevated liver function test (LFT)
values (1.5-2.9 times above the upper limit of normal
or above baseline if abnormal) attributed to voricona-
zole and leading to discontinuation of treatment.
The indication for voriconazole was considered
prophylaxis if the drug was initiated before engraft-
ment for the prevention of fungal infections. For this
study, all other indications for voriconazole, including
secondary prophylaxis while receiving intensive immu-
nosuppression for GVHD and treatment of fungal
infection, were defined collectively as ‘‘all other indica-
tions.’’ These conditions are frequently associated with
additional potential reasons for HT. Duration of ther-
apy was defined as the number of days between the first
dose and the last dose of voriconazole. If the therapywas interrupted for more than 5 days, resumption of
therapy was defined as a second course.
Standards of Care
Prophylaxis against opportunistic infections was
instituted according to the standards of care at
MSKCC. To prevent herpes simplex and varicella zos-
ter virus (VZV) reactivation, acyclovir was given from
beginning of conditioning until immune reconstitu-
tion. Cytomegalovirus (CMV) prophylaxis was not
routinely used. Patients at risk for CMV disease were
monitored and treated if they showed evidence of
CMV reactivation. For Pneumocystis jiroveci prophy-
laxis, trimethoprim/sulfamethoxazole (TMP/SMX)
or pentamidine (in cases of sulfa allergy) were given
from day -7 to day -3, followed by oral TMP/SMX
or inhaled pentamidine from day 130 and continued
until immune reconstitution. Penicillin VK or equiva-
lent was used for prophylaxis against invasive disease
from Streptococcus pneumoniae in patients with cGVHD
or splenectomy.
Recipients of conventional grafts received standard
prophylaxis for GVHD. All patients on cyclosporine
(CsA), tacrolimus, or sirolimus therapy underwent
routine therapeutic drug monitoring of the immuno-
suppressant. An elevated trough level during the ad-
ministration of voriconazolewas defined as. 600 ng/mL
for cyclosporine and .15 ng/mL for tacrolimus and
sirolimus.
For the prevention of invasive fungal infection,
low-risk patients received fluconazole from the day of
admission for HSCT until at least day 175 posttrans-
plantation. Patients with any risk factors for invasive
mold infection (ie, previous possible, probable, or
proven invasive mold infection; GVHD; CMV infec-
tion; HLA-mismatched or unrelated donor; previous
or current extensive corticosteroid use; or age .50
years) received i.v. voriconazole 6mg/kg every 12hours
for 2 doses, then 4 mg/kg every 12 hours starting early
posttransplantation, followed by oral voriconazole 200
mg every 12 hours until at least day175 or cessation of
intensive immunosuppression. Patients with GVHD
or on corticosteroid therapy also received voriconazole
until discontinuation of immunosuppression. Patients
intolerant to voriconazole received i.v. micafungin.
For treatment of mold infections, voriconazole was ad-
ministered at the same dose as for prophylaxis. There
was no routine therapeutic drugmonitoring for vorico-
nazole during the study period. Voriconazole levels
were checked at the discretion of the treating physician.
Data Abstraction and Assessment of Hepatic
Safety
Patients who received .2 consecutive doses of
voriconazole were evaluated for HT. Patient demo-
graphics, primary underlying disease, indication for
200 Evaluable patients 
n=200
HT on voriconazole 
n=68 (34%) 
Discontinuation due to HT 
n= 35 (51%) 
Clinical HT 
n=17 (25%) 
Biochemical HT 
n=51 (75%)
Figure 1. Rates of CL-HT and BIO-HT in 200 patients who received
48 Biol Blood Marrow Transplant 16:46-52, 2010I. Amigues et al.voriconazole, previous concomitant medications, con-
current medical events, and LFT results were obtained
from the electronic medical records. All LFT values
measured from 2weeks before the start of voriconazole
therapy, during therapy, and for 2-4 weeks after the
end of therapy were recorded. The maximum value
for each of the 3 time periods was recorded. Concom-
itant medications were defined as any drugs taken
while on voriconazole therapy. The timing and reasons
for discontinuation of voriconazole, as documented in
the medical record, were recorded.voriconazole. Values in parentheses represent the percentages of total.Statistical Analysis
Descriptive statistics were used to summarize pa-
tient characteristics and safety outcomes. Simple logis-
tic regression was used for univariate analysis of age,
sex, durationof voriconazole therapy (.30days or\30
days), underlying disease (leukemia, myelodysplastic
syndrome [MDS], non-Hodgkin or Hodgkin lym-
phoma [NHL, HL], nonmalignant, or other), donor
type (matched related,matched unrelated,mismatched
related, or mismatched unrelated), stem cell source
(peripheral blood [PBSC], bone marrow [BM], or
cord blood [CB]), graft manipulation (T-cell depletion
or unmodified), conditioning intensity (myeloablative
[MA] or nonmyeloablative [NMA]), conditioning reg-
imen (total body irradiation [TBI]–containing, busul-
fan [Bu]-containing, or other), aGVHD (grade 0-I or
grade II-IV), and indication for voriconazole (prophy-
laxis or all other indications). Fisher’s exact test was
used to determine the significance of the association
between elevated levels of voriconazole or immunosup-
pressants (CsA, tacrolimus, and sirolimus) and HT.
The Wilcoxon signed-rank test was used to assess the
difference between maximum LFT values at baseline,
during treatment, and posttreatment. A P value #.05
was considered significant. All analyseswere performed
using Stata version 8 (StataCorp, College Station, TX).RESULTS
Hepatotoxicity Rate
A total of 334 adult and pediatric patients under-
went allogeneic HSCT at MSKCC during the study
period. A total of 200 patients who received .2 con-
secutive doses of voriconazole and had liver enzyme
monitoring before and during therapy were included
in the study. Of these 200 patients, 117 (58.5%) re-
ceived voriconazole for posttransplantation prophy-
laxis and 83 (41.5%) received voriconazole for all
other indications. The median overall duration of vor-
iconazole therapy was 72 days (range, 1-804 days). The
median duration was 63 days (range, 3-530 days) in pa-
tients withHT and 77 days (range, 1-804 days) in those
without HT.Overall 68 patients (34%) developed HT while on
voriconazole therapy. HT developed after a median of
26 days (range, 0-341 days). Fifty-one patients (75%)
met the criteria for BIO-HT. The remaining 17 pa-
tients (25%) had CL-HT. Figure 1 shows the rates
of HT for the study patients. Voriconazole therapy
was discontinued in 35 patients (51%) with HT. Six
patients were rechallenged with a second course of
voriconazole. Two of these 6 patients discontinued
the second course due to recurrent HT. The second
course of treatment was not included in any of the sub-
sequent analyses.
In 22 of the 68 patients who developed HT (32%),
HT occurred contemporaneously with major diagno-
ses associated with HT, including GVHD of the liver
or gut (n 5 11), VOD of the liver (n 5 3), sepsis with
multisystem organ failure (n 5 4), acute infectious
hepatitis (n5 1), major bleeding leading to TBil eleva-
tion (n 5 1), and cholecystitis (n 5 2). Although we
cannot exclude the contribution of voriconazole to
the HT, the presentation and temporal association of
HT in these patients was more consistent with alterna-
tive causes.Assessment of Hepatic Dysfunction
In the patients who experienced BIO-HT, we
compared the maximum values of liver enzymes at
baseline, during treatment, and after discontinuation
of voriconazole to assess the magnitude and reversibil-
ity of HT. Figure 2 shows boxplots of LFT values for
these 3 time points. For the majority of patients, the
maximum elevations in AST, ALT, TBil, and Alk
Phos were moderate during treatment. Posttreatment
values of AST, ALT, and Alk Phos were significantly
lower than the values during treatment and were sim-
ilar to baseline values. Posttreatment TBil was similar
to that during treatment and significantly higher than
baseline (P5 .02). Ten patients had elevated TBil and
underwent follow-upmonitoring after discontinuation
of voriconazole. In 6 of these 10 patients (60%), HT
was attributable to other causes; in the other 4 patients,
TBil value returned to normal.
Figure 2. Changes in LFT values during and after voriconazole treatment in patients with HT. Twenty-four patients met the criteria for BIO-HT based
on ALT, 28 did so based on AST, 18 did so based on Alk Phos, and 20 did so based on TBil. Boxplots were created to illustrate the difference in maximum
values for ALT, AST, Alk Phos, and TBil at baseline, during treatment, and posttreatment in patients with BIO-HT. Shaded regions represent the inter-
quartile range (IQR). Capped whiskers represent the upper and lower adjacent values (the highest value within 1.5 times the IQR of the upper or lower
bound of the IQR). Outliers are excluded. To assess hepatic dysfunction during voriconazole treatment, we compared LFT values at baseline with those
during treatment. The values during treatment were significantly higher than baseline values for all LFTs examined. To assess the reversibility of hepatic
dysfunction, we compared the values at the end of treatment with those posttreatment. Posttreatment ALT, AST, and Alk Phos values were significantly
lower than during treatment and not different from baseline. The posttreatment TBil value was significantly higher than baseline.
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the discontinuation of voriconazole and did not have
posttreatment LFTs. Voriconazole HT was not con-
sidered to contribute to death in any of these 15 pa-
tients. Causes of death included septic shock with
multisystem organ failure (n5 7), relapsed underlying
malignancy (n54), alveolar hemorrhage (n 5 2), and
VOD (n 5 2).Risk Factors for Hepatotoxicity
Table 1 compares the characteristics of the 68 pa-
tients who developedHT and the 132 patients who did
not. We conducted simple logistic regression to iden-
tify risk factors for HT. All of the variables listed in
Table 1 were included in the analysis as putative risk
factors for HT. Table 2 gives significant variables.
Acute GVHD was a risk factor for HT (odds ratio
[OR]52.98; 95% confidence interval [CI]5 1.52-5.85;
P 5 .001). This was supported by an association
between the receipt of a T-cell depleted graft and
less HT (OR 5 0.51; 95% CI 5 0.28-0.93; P 5 .027).
In multivariate analyses, HT was associated withaGVHDgrade II-IV (OR5 3.17; 95%CI5 1.50-6.68;
P 5 .002).Concomitant Medications
Themajority of patients received multiple medica-
tions known to cause HT alone or synergistically with
voriconazole. The most commonly used concomitant
medications with a potential for HT are listed in
Table 3. Overall, there was no substantial difference
in the utilization of each major category of concomi-
tant medications between the patients who developed
HT while on voriconazole and those who did not.
Ten patients (15%) with HT had received concomi-
tant agents that were temporally related and likely con-
tributed to HT, including antifungal agents (n 5 5),
oral contraceptives (n5 3), deferasirox (n5 1), and an-
abolic steroids (n 5 1).
During the study period, voriconazole levels were
monitored at the discretion of the clinician. Steady-
state trough levels of voriconazole were checked in
36 patients who developed HT and in 29 patients
who did not develop HT. Three patients (8.3%) with
Table 1. Characteristics of Patients with and without HT
Receiving Voriconazole
Characteristic HT (n 5 68) No HT (n 5 132)
Age, years
Median, years 41.5 47.6
Age <12 years (n 5 19), n (%) 7 (10.3) 12 (9.1)
Age >12 years (n 5 181), n (%) 61 (89.7) 120 (90.9)
Sex, n (%)
Male 43 (63.2) 76 (57.6)
Female 25 (36.8) 56 (42.4)
Voriconazole exposure, n (%)
30 days or less 25 (36.8) 40 (30.3)
More than 30 days 43 (63.2) 92 (69.7)
Underlying disease, n (%)
Leukemia 33 (48.5) 67 (50.8)
Myelodysplastic syndrome 11 (16.2) 23 (17.4)
Non-Hodgkin lymphoma 16 (23.5) 21 (15.9)
Hodgkin lymphoma 4 (5.8) 7 (5.3)
Nonmalignant 2 (2.9) 7 (5.3)
Other 2 (2.9) 7 (5.3)
Donor type, n (%)
Matched-related 18 (26.5) 43 (32.6)
Matched-unrelated 21 (30.9) 42 (31.8)
Mismatched-related 2 (2.9) 4 (3.0)
Mismatched-unrelated 27 (39.7) 43 (32.6)
Stem cell source, n (%)
Peripheral blood 50 (73.5) 105 (79.6)
Bone marrow 4 (5.9) 14 (10.6)
Cord blood 14 (20.6) 13 (9.9)
Graft manipulation, n (%)
Unmodified 38 (55.9) 52 (39.4)
T-cell depleted 30 (44.1) 80 (60.6)
Conditioning intensity, n (%)
Nonablative 21 (30.9) 28 (21.2)
Ablative 47 (69.1) 104 (78.8)
Conditioning regimen, n (%)
Busulfan-containing 17 (25.0) 51 (38.6)
Total body irradiation–containing 38 (55.9) 65 (49.2)
Other non–total body irradiation 13 (19.1) 16 (12.1)
Acute GVHD, n (%)
Grade 0-I 37 (59.7) 106 (81.5)
Grade II-IV 25 (40.3) 24 (18.5)
Not evaluable (n58)
Indication for voriconazole, n (%)
Prophylaxis 41 (60.3) 76 (57.6)
All other indications 27 (39.7) 56 (42.4)
HT indicates hepatotoxity; GVHD, graft-versus-host disease.
Table 2. Univariate Analysis of Risk Factors for HTWhile on
Voriconazole*
OR 95% CI P
T-cell depletion
Unmodified 1.00 - -
T-cell depleted 0.51 0.28-0.93 .027
GVHD†
Grade 0-I 1.00 - -
Grade II-IV 2.98 1.52-5.85 .001
Stem cell source
Peripheral blood 1.00 - -
Bone marrow 0.60 0.19-1.92 .389
Cord blood 2.26 0.99-5.17 .053
HT indicates hepatotoxicity; OR, odds ratio; CI, confidence interval;
GVHD, graft-versus-host disease.
*The variables listed in Table 1 were included in the model. Significant
variables are shown.
†Eight patients with nonevaluable acute GVHDwere excluded from this
analysis.
Table 3. Concomitant Medication Use in Patients with and
without HT
Agent
HT No HT
(n 5 68) (n 5 132)
Antiviral, n (%)
Acyclovir 50 (73.5%) 108 (81.8%)
Ganciclovir 4 (5.9%) 8 (6.1%)
Valganciclovir 17 (25%) 32 (24.2%)
Foscarnet 6 (8.8%) 14 (10.6%)
Cidofovir 2 (2.9%) 5 (3.8%)
PCP prophylaxis, n (%)
Dapsone 1 (1.5%) 1 (0.8%)
TMP/SMX 11 (16.2%) 29 (22.0%)
Atovaquone 14 (20.6%) 37 (28.0%)
Pentamidine 36 (52.9%) 67 (50.8%)
Antifungals
Micafungin 29 (42.7%) 42 (31.8%)
Amphotericin B 7 (10.29%) 2 (1.5%)
Immunosuppressants
Cyclosporin A 27 (39.7%) 36 (27.2%)
Tacrolimus 15 (22.0%) 23 (17.4%)
Sirolimus 2 (2.9%) 14 (10.6%)
Mycophenolate mofetil 25 (36.7%) 32 (24.2%)
Budesonide 12 (17.7%) 13 (9.9%)
Other immunosuppressants* 3 (4.4%) 4 (3.03%)
Corticosteroids 34 (50%) 46 (34.9%)
Calciumchannel blocker
50 Biol Blood Marrow Transplant 16:46-52, 2010I. Amigues et al.HT and 4 patients (13.8%) without HT had at least
one trough level.6mg/L (P5 not significant). All pa-
tients receiving CsA, tacrolimus, or sirolimus had rou-
tine therapeutic drug monitoring. An elevated trough
level was noted in 26 of the 63 patients on cyclospor-
ine, in 21 of the 38 patients on tacrolimus, and in 3 of
the 16 patients on sirolimus. The proportion of ele-
vated trough levels was not significantly different be-
tween patients with and without HT: cyclosporine,
44% vs 39% (P 5 .97); tacrolimus, 73% vs 44% (P
5 .35); sirolimus, 50% vs 14.3% (P 5 .69).Amlodipine 5 (7.4%) 3 (2.3%)
Psychotropics
Olanzapine 10 (14.7%) 24 (18.2%)
Lorazapam 23 (33.8%) 57 (43.2%)
Zolpidem 12 (17.7%) 27 (20.5%)
Other† 13 (19.1%) 33 (25.0%)
*Includes alemtuzumab and methotrexate.
†Includes escitalopram, citalopram, dronabinol. clonazepam, gabapentin,
and alprazolam.DISCUSSION
Evaluating the hepatic safety of medications in
HSCT recipients is challenging because of frequent
confounding conditions and medications associated
with hepatic abnormalities [15-17]. Our observationalstudy is the largest assessment of the hepatic safety of
voriconazole in allogeneic HSCT to date outside the
context of a randomized, controlled clinical trial. We
analyzed HT based on the measurement of serum
transaminase level. The assessment of CL-HT was
partly subjective.
The exposure to voriconazole was long, with a
median of 72 days. HT occurred at a median of 26
days of therapy. Approximately one-third of the
Biol Blood Marrow Transplant 16:46-52, 2010 51Safety of Voriconazole in HSCTpatients (34%) developed HT during voriconazole
therapy. This is higher than the rate of 19% reported
in previous randomized clinical trials of voriconazole
[13]. Determining the causality of HT in relation to
voriconazole in our cohort was extremely difficult.
Almost half of our patients had other concomitant
conditions or medication exposures causing or contrib-
uting to HT. Some patients with mild transaminase
changes continued voriconazole therapy with their
transaminase values improving or remaining only
mildly elevated.
Because the majority of the allogeneic HSCT re-
cipients at MSKCC receive voriconazole prophylaxis,
identifying a comparator cohort of patients who did
not receive voriconazole and had similar characteris-
tics as our study cohort was not feasible. Thus, to iden-
tify risk factors for HT, we compared the patients who
developed HT while on voriconazole to the patients
who did not. In multivariate analyses, only aGVHD
grade II-IV remained a significant risk factor for HT.
Our patients’ extensive exposure to other poten-
tially hepatotoxic medications posed an additional
challenge in the assessment of competing causes for
HT. CsA, tacrolimus, warfarin, and calcium channel
blockers can cause HT and have a known pharmacoki-
netic interaction with voriconazole. A comparison of
the use of immunosuppressants and other hepatotoxic
drugs in patients who developed HT and those who
did not revealed no substantial differences between
the 2 groups (all P . .1). The proportion of patients
with an elevated level of a calcineurin inhibitor (cyclo-
sporine and tacrolimus) or an mTOR inhibitor (siroli-
mus) did not differ significantly between the 2 groups.
Interestingly, in univariate analysis, recipients of
T-cell depleted grafts, who did not require additional
exogenous immunosuppression for GVHD prophy-
laxis, were less likely to developHT compared with re-
cipients of unmodified grafts. A lack of exogenous
immunosuppression or lower rates of GVHD in the
recipients of T-cell depleted grafts may account for
this finding.
Voriconazole is extensively metabolized by the
liver. Cytochrome CYP2C19, the major enzyme re-
sponsible for voriconazole metabolism, exhibits ge-
netic polymorphisms that result in variations in
voriconazole metabolism and exposure. Poor metabo-
lizers may experience up to a 4-fold increase in drug
exposure; such a phenotype is found in up to 20% of
non-Indian Asians, but in only 3%-5% of Caucasians
and African Americans [18]. Our population included
only 9 Asian patients (4%). The association between
HT and elevated voriconazole levels is not well de-
fined. An elevated voriconazole trough level has been
associated with HT, which certainly is of concern in
HSCT recipients who are already at risk for liver dys-
function [19-23]. Because therapeutic drug monitor-
ing was done at the discretion of clinicians in ourstudy, the possibility of testing bias is plausible.
Patients with LFT abnormalities or those requiring
a high dose of voriconazole would be more likely to
have their levels checked. Nonetheless, we did not ob-
serve any significant differences between the 2 groups
in the number of patients with a voriconazole trough
level .6 mg/L.
Our assessment of the trend of transaminase values
with time revealed a significant decrease in all enzymes
except TBil after withdrawal of therapy. The TBil
elevations could be explained by the presence of other
conditions and comorbidities in the majority of pa-
tients. Our data strongly suggest that HT was largely
reversible after discontinuation of voriconazole. Al-
though there was a temporal association between the
increased transaminase values with voriconazole treat-
ment and decreased values with discontinuation of
treatment in many patients with HT, a causal relation-
ship is less clear. In a review of the medical records of
patients who developed HT and died while on vorico-
nazole therapy, voriconazole was not considered to
contribute to death in any of these patients.
In summary, in this large cohort of high-risk
HSCT recipients, 34% of the patients experienced
mild to moderate elevations in liver enzymes. All of
the abnormalities except elevated TBil were reversible
after stopping voriconazole. aGVHD was a significant
risk factor for HT. Approximately 50% of the patients
had concomitant diagnoses or medications associated
with HT. In approximately 50% of the patients,
LFT abnormalities normalized or remained only
mildly elevated and did not necessitate discontinuation
of voriconazole therapy. Voriconazole therapy with
monitoring appears reasonably safe in HSCT recipi-
ents at high risk for invasive fungal infections.ACKNOWLEDGMENTS
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